OBJECTIVE -To determine whether short-term improvement in pancreas graft survival with simultaneous pancreas-kidney (SPK) transplants translated into improved long-term survival, then to examine the implications of that determination.
S
imultaneous pancreas-kidney (SPK) transplants account for over 78% of current pancreas allografts (1) (2) (3) . Expectations for SPK started high, especially when technical and immunosuppressive advances yielded marked improvements in 1-year and 3-year graft survival rates through 2004, as shown on the International Pancreas Transplant Registry (IPTR) Web site (2) and by previous studies (3) (4) (5) (6) . But the focus of these studies, like clinical focus, has been on relatively short-term survival. The question remains: Has that translated into improved long-term-5-year-plus-SPK pancreas graft survival? This study's objective was to determine the answer, then examine the implications. We also examined causes of chronic pancreas graft dysfunction and other factors that may influence evaluation of SPK as therapy for diabetes. (Fig. 1A) . These rates were similarly high among recipients transplanted in the eras 1995-1999, 2000 -2004, and 2005-2007 . Limiting analysis to grafts surviving over 1 year, 5-year SPK survival rates after 1990 were almost identical in the different eras (Fig. 1B) , and SPK offered much better survival than pancreas-afterkidney (PAK) transplant and pancreas transplant alone (PTA): 10-and 15-year survival was 62 and 40%, respectively, for SPK only 36 and 11% for PAK, and 32 and 18% for PTA (3) . Yet SPK offers distinct quality-of-life (QOL) benefits: freedom from selfadministered insulin, more stable blood glucose levels, and no risk of hypoglycemia (7-9). Furthermore, right now there seems to be no realistic alternative that affords the same QOL as SPK for type 1 diabetic patients with end-stage renal disease. Survival is comparable for livingdonor kidney transplants and SPK transplants (10), but kidney transplants alone offer diabetic individuals only marginal QOL improvement in freedom from insulin injection or having more stable glycemic control; and the supply of living donor kidneys is still limited.
RESEARCH DESIGN AND METHODS
The 1-year-survived chronic pancreas graft failure rate at 10 and 15 years was lowest with SPK (28 and 60%, respectively) compared with PAK (64 and 89%) and PTA (68 and 82%) (3)-an important consideration because monitoring of function or biopsy of an SPK kidney may also provide warning of possible pancreas graft chronic rejection early enough for more timely and effective intervention, a benefit not obtained with PAK or, obviously, PTA (11) . This predictive feature of SPK is slightly compromised because, although (excluding firstyear graft failures) 5-year pancreas and kidney survivals were comparable (84 and 83%, respectively), 10-year survival was 63% (pancreas) and 59% (kidney) (3) . Nevertheless, early warning should, intuitively, result in improved long-term graft survival. The reason it has not is because, as of now, there is no established, even remotely definitive treatment for chronic rejection-which, as we have shown above, is the major long-term cause of graft dysfunction and loss.
That leads to the real implication of our study's new finding. There will evidently be no "natural" improvement in long-term pancreas graft survival that might be expected after such great shortterm improvement. So the next step must be the same level of concentration on elucidating the mechanism of chronic rejection and developing a therapy as effective as that for reducing short-term graft loss.
Meanwhile, the clinical decision as to whether the QOL benefits and predictive feature of SPK offset any contraindications should be weighed for each patient, individually, and the new knowledge that, right now, long-term survival has not improved constituting one more factor to be weighed.
